LB Pharmaceuticals, Inc. (LBRX) AI Stock Analysis

• Market Cap: $542.67M
• Dividend Yield: N/A
• Average Volume (3M): 347.37K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 25,299,103
• 10 Day Avg. Volume: 178,624
• 30 Day Avg. Volume: 347,371
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.14
• Enterprise Value/Market Cap: 0.51
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -17.13
• 1Y Price Target: $48.00
• Price Target Upside: 123.78% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $24.00 ▲(11.89% Upside)

The score is primarily held back by weak financial performance: no revenue, a sharp 2024 step-up in losses and cash burn, and deeply negative equity that elevates financing and dilution risk. Technical indicators are moderately supportive (positive MACD, neutral RSI, trading above the 50-DMA), but valuation support is limited due to missing P/E and dividend yield data.

LB Pharmaceuticals, Inc. Business Overview & Revenue Model

Company Description

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

How the Company Makes Money

LB Pharmaceuticals, Inc. Financial Statement Overview

Summary

Pre-revenue with sharply worsening fundamentals: 2024 net loss deteriorated to about -$63.1M and operating/free cash flow fell to roughly -$53M, indicating rapidly rising cash burn. Balance sheet flexibility is constrained by deeply negative equity (about -$94.6M in 2024), increasing external financing/dilution risk despite relatively modest debt (~$3.7M).

Income Statement

The company reports no revenue across 2022–2024, consistent with an early-stage biotech profile, but losses are widening sharply. Net loss expanded from about $14.3M (2022) to $6.3M (2023) and then deteriorated materially to about $63.1M (2024), indicating a significantly higher expense base. With no revenue and deeply negative operating results, near-term profitability visibility is limited.

Balance Sheet

The balance sheet is pressured by persistent negative equity, which deepened meaningfully from roughly -$34.5M (2023) to about -$94.6M (2024), signaling accumulated losses and weak balance-sheet resilience. Total debt is relatively modest in 2024 (~$3.7M) versus prior periods, but negative equity reduces financial flexibility and can raise financing risk despite the low absolute debt level.

Cash Flow

Cash burn intensified significantly: operating cash flow declined from about -$12.1M (2023) to roughly -$53.1M (2024), with free cash flow similarly around -$53.8M in 2024. While free cash flow is roughly in line with net loss (suggesting losses are largely cash-based rather than accounting-only), the scale and acceleration of cash outflows materially increase funding needs and dilution/financing risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00
EBITDA	-16.15M	-63.01M	-1.45M	-12.19M
Net Income	-16.15M	-63.10M	-6.28M	-14.35M
Balance Sheet
Total Assets	74.26M	33.53M	45.66M	21.49M
Cash, Cash Equivalents and Short-Term Investments	72.13M	28.00M	43.29M	21.40M
Total Debt	0.00	3.70M	0.00	24.15M
Total Liabilities	124.71M	128.09M	80.13M	50.30M
Stockholders Equity	-50.45M	-94.55M	-34.47M	-28.81M
Cash Flow
Free Cash Flow	-9.62M	-53.82M	-12.12M	-2.73M
Operating Cash Flow	-9.57M	-53.05M	-12.09M	-2.73M
Investing Cash Flow	-26.06M	23.23M	-28.01M	123.00K
Financing Cash Flow	38.29M	38.31M	33.68M	22.96M

LB Pharmaceuticals, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LBRX	49 Neutral	$542.67M	―	―	―	―	―
HIND	46 Neutral	$10.84M	-0.01	-565.18%	―	-48.74%	89.18%
ENVB	42 Neutral	$4.05M	-0.03	-262.78%	―	―	79.45%

LB Pharmaceuticals, Inc. Corporate Events

LB Pharmaceuticals Expands Lease at One Penn Plaza

On November 10, 2025, LB Pharmaceuticals Inc. amended its lease agreement with One Penn Plaza LLC to include an additional 4,634 square feet on the 10th floor of One Penn Plaza, New York. The lease term is set to expire on March 31, 2032, with the expansion premises expected to be delivered by July 1, 2026. The initial fixed rent for the expansion will be $430,962 annually for the first three years, increasing to $477,302 thereafter, with a rent abatement period agreed upon for the first 150 days.

The most recent analyst rating on (LBRX) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on LB Pharmaceuticals, Inc. stock, see the LBRX Stock Forecast page.

LB Pharmaceuticals Appoints New Chief Commercial Officer

On November 12, 2025, LB Pharmaceuticals announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer, effective November 10, 2025. With over 20 years of experience in the biopharmaceutical industry, particularly in neuroscience commercialization, Ms. Pai Panandiker’s leadership is expected to be pivotal as the company advances LB-102 toward registration and commercialization. Her expertise in launching and scaling global brands will be crucial for LB Pharmaceuticals as it prepares to bring its innovative therapy for schizophrenia and bipolar depression to market.

The most recent analyst rating on (LBRX) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on LB Pharmaceuticals, Inc. stock, see the LBRX Stock Forecast page.